Tesamorelin

About Tesamorelin

Tesamorelin is a synthetic version of human growth hormone releasing hormone (hGHRH 1-44). Scientists have chemically tweaked it by adding a trans-3-hexenoyl group at the N-terminus – this clever modification boosts its stability and makes it work better. Here's how it works: the peptide acts as a selective growth hormone releasing hormone receptor agonist. It stimulates your pituitary gland to release natural growth hormone whilst keeping the body's normal pulsing secretion pattern intact. That's pretty important for maintaining natural hormone rhythms. Research shows Tesamorelin is particularly good at targeting visceral fat – the stubborn stuff around your organs – and improving how your body handles lipids through the GH/IGF-1 pathway. Clinical studies have found it significantly reduces belly fat without touching subcutaneous fat (the fat under your skin). This makes it really valuable for metabolic research. The peptide's unique structure gives it much better plasma stability than natural GHRH. It's got a half-life that works well for research protocols too. Our pharmaceutical-grade Tesamorelin comes as a freeze-dried powder with over 98% purity – we've verified this through HPLC analysis. Each vial contains precisely measured quantities so you get consistent results in your experiments. This product is exclusively for in vitro laboratory research and isn't for human consumption or therapeutic use.

Research Applications

• Studied for its role in GHRH receptor binding and stabilised half-life relative to native hGHRH 1-44.
• Investigated for association with visceral adipose tissue lipolysis pathways in preclinical models.
• Researched for involvement in IGF-1 axis modulation and hepatic somatotroph signalling.
• Examined for its role in lipid metabolism and triglyceride flux in cultured adipocyte models.

Research Mechanism — Tesamorelin

A simplified summary of what Tesamorelin is studied for in research models. For laboratory in-vitro use only.

1. 1

   Molecular target

   A stabilised GHRH analogue investigated for its binding to pituitary somatotroph receptors and its activation of cAMP-coupled signalling in research models.

   • Growth hormone-releasing hormone receptor (GHRH-R)
   • Gαs-coupled adenylyl cyclase complex
   • Pit-1 transcription factor regulatory axis
2. 2

   Investigated pathways

   Preclinical studies have explored downstream effects on cAMP–PKA signalling, somatotroph gene expression, and IGF-1 axis responses in cultured pituitary cells.

   • cAMP–PKA–CREB signalling cascade
   • Somatotroph GH gene-expression assays
   • Hepatic IGF-1 transcriptional response
3. 3

   Preclinical research applications

   Used as a research tool in laboratory models exploring pituitary endocrinology, lipid-metabolism science, and visceral-adipose research. Not approved for human use.

   • Somatotroph cell-line GH secretion assays
   • Visceral adipocyte lipolysis models
   • GH–IGF-1 axis preclinical studies

For research use only. Tesamorelin is not approved as a medicine in the UK and is not intended for human or veterinary administration. See the compliance page for full terms.